文献速递肺外科

纯磨玻璃影特征肺腺癌术后十年随访结果

Ten-Year Follow-up Results of Pure Ground-Glass Opacity-Featured Lung Adenocarcinomas After Surgery.
PubMed 文献 · Ann Thorac Surg · 2023-01-13

本研究回顾2007年12月至2013年12月手术的纯磨玻璃影特征肺腺癌患者308例,中位随访112个月,10年无复发生存率100%,10年总生存率96.9%,5年与10年肺癌特异性生存率均为100%,肺叶切除与亚肺叶切除的10年无复发生存率无差异(P=0.697),术后10年第二原发肺癌风险2.4%,与EGFR突变状态无关(P=0.452)。

要点

  • 纯磨玻璃影特征肺腺癌术后10年无复发生存率100%,5年与10年肺癌特异性生存率均为100%。
  • 肺叶切除与亚肺叶切除的10年无复发生存率无差异(P=0.697)。
  • 术后10年第二原发肺癌风险2.4%,与EGFR突变状态无关(P=0.452)。

核心结论

  • 纯磨玻璃影特征肺腺癌术后10年未观察到复发,即使病理评估为浸润性腺癌。
  • 纯磨玻璃影可经手术治愈,推荐在适当时机行手术治疗以期治愈。
  • 研究强调影像学纯磨玻璃影特征肺腺癌应与其他肺腺癌区分。

研究设计与样本

  • 回顾性分析2007年12月至2013年12月接受手术的肺腺癌患者,纳入纯磨玻璃影特征肺腺癌308例。
  • 分析术后生存及第二原发肺癌发生风险。

主要发现

  • 308例中女性226例(73.4%),非吸烟者268例(87.0%),接受亚肺叶切除187例(60.7%)。
  • 术后中位随访112个月,10年无复发生存率100%,10年总生存率96.9%,5年与10年肺癌特异性生存率均为100%。
  • 肺叶切除与亚肺叶切除患者的10年无复发生存率无差异(P=0.697)。
  • 接受突变分析的患者中EGFR突变检出率为55.6%(151例中84例)。
  • 术后10年第二原发肺癌风险为2.4%,与EGFR突变状态无关(P=0.452)。

临床怎么用

  • 作者认为纯磨玻璃影特征肺腺癌可经手术治愈,推荐在适当时机行手术治疗以期治愈。
  • 作者强调影像学纯磨玻璃影特征肺腺癌应与其他肺腺癌区分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previously, we have demonstrated that the 5-year recurrence-free survival after surgery of pure ground-glass opacity (GGO)-featured lung adenocarcinoma is 100%. This study aimed to reveal the long-term outcomes of these patients 10 years after surgery. METHODS: Lung adenocarcinoma patients who underwent surgery between December 2007 and December 2013 were reviewed. Patients with pure GGO-featured lung adenocarcinoma were enrolled. Postoperative survival and the risk of developing second primary lung cancer were analyzed. RESULTS: Overall, 308 cases of pure GGO-featured lung adenocarcinomas were included. Of these patients, 226 (73.4%) were female, 268 (87.0%) were nonsmokers, and 187 (60.7%) underwent sublobar resection. The median follow-up period after surgery was 112 months. The 10-year recurrence-free survival rate of these patients was 100%, and 10-year overall survival rate was 96.9%. Both 5-year and 10-year lung cancer-specific survival were 100%. There was no difference in 10-year recurrence-free survival rates between patients who underwent lobectomy or sublobar resection (P = .697). EGFR mutations were detected in 55.6% (84 of 151) of patients who underwent mutational analysis. The risk of developing secondary primary lung cancer for pure GGO-featured lung adenocarcinoma patients at 10 years after resection was 2.4%, and was not correlated with EGFR mutation status (P = .452). CONCLUSIONS: No recurrence was observed in patients with pure GGO-featured lung adenocarcinomas 10 years after surgery, even when pathologically evaluated as invasive adenocarcinoma. Pure GGO can be cured by surgery. Surgery is recommended for the appropriate time window with the view to cure. Our study emphasizes that radiologic pure GGO-featured lung adenocarcinomas should be distinguished from other lung adenocarcinomas.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Li D, Deng C, Wang S, et al. Ten-Year Follow-up Results of Pure Ground-Glass Opacity-Featured Lung Adenocarcinomas After Surgery. Ann Thorac Surg. 2023. PMID: 36646243. doi:10.1016/j.athoracsur.2023.01.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。